For example, evaluation of cell cycle derangement in thyroid tumors may serve as a useful tool for both DTC diagnosis and prognosis [26]; PLK1 and AK inhibitors display the potential for being employed in innovative therapeutic strategies for improving T-ALL patient outcome [27]; Inhibition of Aurora and Polo-like kinases suggest that targeting G2-M regulators may represent a novel approach for treatment of human [28]. The gene discussed is PLK1; the disease is acute lymphoblastic leukemia.